StockNews.com started coverage on shares of Invitae (NYSE:NVTA – Get Free Report) in a research note issued to investors on Sunday. The brokerage set a “hold” rating on the medical research company’s stock. Separately, The Goldman Sachs Group cut their target price on Invitae from $1.00 to $0.50 and set a “sell” rating for the […]